BioMark Contributes in Scientific Publication

Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA.

 

Rashid Ahmed, President and CEO, says, “We are extremely excited to have worked with a great team of clinicians, scientists and researchers to realize this important publication. It provides confirmation that one of our technology platforms has an important clinical application in the cancer biomarker space. We would like to thank each of the contributing members of the team and express our sincere gratitude to all supporting organizations that made this possible.”

 

“BioMark is looking forward to publishing additional peer reviewed papers in the near term on significant discoveries that it has invested resources over the past few years. BioMark’s technology platform will be appreciated by both clinicians and researchers focused on introducing disruptive technology to help better manage cancer,” says Rashid.

 

The paper is available through open access at https://www.future-science.com/doi/full/10.4155/fsoa-2018-0077. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

 

About Future Science OA

Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery, delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold open access journal, Future Science OA, also embraces the importance of publishing all good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health.

Future Science Journals

Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge information on the most exciting emerging trends in their field of endeavour.

Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for more information, see Subscriptions and Pricing).

Contact:

Laura Dormer, Editorial Director

Future Science Group,
Unitec House,
2 Albert Place,
London,
N3 1QB, UK

Press Release – BioMark Contributes in Scientific Publication

Share this post:
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.